References

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

10.1016/s0140-6736(10)61350-5 · 2010 · External reference

Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis

10.1001/jama.2016.13985 · 2016 · External reference

Safety of anacetrapib in patients with or at high risk for coronary heart disease

10.1056/nejmoa1009744 · 2010 · External reference

Effects of dalcetrapib in patients with a recent acute coronary syndrome

10.1056/nejmoa1206797 · 2012 · External reference

Evacetrapib and cardiovascular outcomes in high-risk vascular disease

10.1056/nejmoa1609581 · 2017 · External reference

Effects of anacetrapib in patients with atherosclerotic vascular disease

10.1056/nejmoa1706444 · 2017 · External reference

Safety and efficacy of obicetrapib in patients at high cardiovascular risk

2025 · External reference

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease

10.1093/eurheartj/ehab863 · 2022 · External reference

Effects of torcetrapib in patients at high risk for coronary events

10.1056/nejmoa0706628 · 2007 · External reference

Cholesteryl ester transfer protein inhibitors and cardiovascular outcomes: a systematic review and meta-analysis

10.3390/jcdd11050152 · 2024 · External reference

Comparative effectiveness of Cholesteryl Ester Transfer Protein (CETP) inhibitors on lipid profiles in adults with hyperlipidemia: a comprehensive systematic review and frequentist network meta-analysis of randomized controlled trials

10.1002/clc.70204 · 2025 · External reference

Obicetrapib and its impact on lipid parameters: a comprehensive meta-analysis of the latest evidence

10.1016/j.jacl.2025.07.003 · 2025 · External reference

Cholesteryl ester transfer protein inhibitors for dyslipidemia in cardiovascular risk patients: a systematic review and meta-analysis

10.69854/jcq.2025.0030 · 2025 · External reference

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

10.1136/bmj.n71 · 2021 · External reference

Rayyan—A web and Mobile app for systematic reviews

10.1186/s13643-016-0384-4 · 2016 · External reference

RoB 2: a revised tool for assessing risk of bias in randomised trials

10.1136/bmj.l4898 · 2019 · External reference

Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies

10.1093/eurheartj/ehx144 · 2017 · External reference

HDL cholesterol efflux capacity and incident cardiovascular events

10.1056/nejmoa1409065 · 2014 · External reference

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

10.1016/s0140-6736(12)60312-2 · 2012 · External reference

Are surrogate markers adequate to assess cardiovascular disease drugs?

1999 · External reference